New Zealand markets open in 8 hours 26 minutes

AbbVie Inc. (ABBV)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
172.32+1.18 (+0.69%)
At close: 04:00PM EDT
172.32 0.00 (0.00%)
After hours: 07:59PM EDT

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees50,000

Key executives

NameTitlePayExercisedYear born
Mr. Richard A. GonzalezExecutive Chairman7.19MN/A1954
Mr. Robert A. MichaelCEO & Director4.62MN/A1970
Mr. Scott T. ReentsExecutive VP & CFO3.13MN/A1968
Dr. Azita Saleki-Gerhardt Ph.D.Executive VP & COO3.51M5.25M1963
Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer4.32M2.13M1969
Dr. Roopal Thakkar M.D.Executive VP of Research and Development & Chief Scientific OfficerN/AN/A1972
Ms. Elizabeth SheaSenior Vice President of Investor RelationsN/AN/AN/A
Mr. Perry C. SiatisExecutive VP, General Counsel & SecretaryN/AN/A1975
Mr. Sanjay NarayanSenior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic LegalN/AN/AN/A
Mr. Timothy J. RichmondExecutive VP & Chief Human Resources Officer1.12MN/A1966
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Corporate governance

AbbVie Inc.’s ISS governance QualityScore as of 1 July 2024 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.